Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

AstraZeneca And Bristol-Myers Squibb Receive European Approval For Forxiga Tablets

share with twitter share with LinkedIn share with facebook
11/14/2012 | 12:12pm EDT

LONDON--AstraZeneca PLC (>> AstraZeneca plc), a biopharmaceutical company, and Bristol-Myers Squibb (>> Bristol Myers Squibb Co.), said Wednesday that the European Commission has approved Forxiga(>> TOYOTA MOTOR CORPORATION) (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union.

MAIN FACTS:

-Forxiga is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments for type 2 diabetes.

-Shares at 1652 GMT down 1%, at 2856 pence, valuing the company at GBP35 billion.

-Write to Mark Shapland at mark.shapland@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.01% 8542 Delayed Quote.12.29%
ASTRAZENECA PLC -1.41% 979 Delayed Quote.5.62%
BRISTOL-MYERS SQUIBB COMPANY -0.63% 63.24 Delayed Quote.-1.48%
TOYOTA MOTOR CORPORATION 0.57% 7285 End-of-day quote.-5.56%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
02:04pEU to enter contract talks with J&J over 200 million doses of potential COVID..
RE
01:16pNEWS HIGHLIGHTS : Top Company News of the Day
DJ
12:17pASTRAZENECA : Mexico, Argentina to Produce Potential AstraZeneca Coronavirus Vac..
DJ
12:14pU.S. recruits scientists abroad for COVID-19 vaccine trials, pledges access t..
RE
10:11aEUROPE : European stocks end four-day winning run as UK's FTSE drags
RE
08:19aVaccine ETA? Depends who you ask
RE
08:03aIndian drugmaker Biological E. to make substance used in J&J's potential COVI..
RE
07:31aASTRAZENECA : Ships FLUMIST® QUADRIVALENT Vaccine in the US for 2020-2021 Flu Se..
BU
08/13ASTRAZENECA PLC : Ex-dividend day for interim dividend
FA
08/11U.S. inks $1.5 billion deal with Moderna for 100 million doses of COVID-19 va..
RE
More news
Financials (USD)
Sales 2020 26 712 M - -
Net income 2020 3 067 M - -
Net Debt 2020 13 578 M - -
P/E ratio 2020 51,2x
Yield 2020 2,52%
Capitalization 147 B 147 B -
EV / Sales 2020 5,99x
EV / Sales 2021 5,26x
Nbr of Employees 70 600
Free-Float 95,7%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 113,90 $
Last Close Price 111,64 $
Spread / Highest target 30,4%
Spread / Average Target 2,02%
Spread / Lowest Target -46,3%
EPS Revisions
Managers
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC14.36%148 927
JOHNSON & JOHNSON0.75%394 028
ROCHE HOLDING AG1.08%297 694
PFIZER, INC.-2.17%212 995
MERCK & CO., INC.-9.09%209 118
NOVARTIS AG-15.76%187 147